Abstract
Background: Reslizumab, a biologic targeting IL-5, has been shown to reduce asthma exacerbations and maintenance oral corticosteroid use in randomized controlled trials and pre-post studies in patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce, and it is unknown whether reslizumab has added value after switching from another type 2 biologic. Objective: To evaluate (1) the real-world effectiveness of reslizumab on severe asthma exacerbations, maintenance oral corticosteroid use, and overall treatment response, both in biologic-naive patients who initiated reslizumab and in those who switched from another type 2 biologic; and (2) physicians’ experience with reslizumab treatment. Methods: This observational real-world study evaluated data from 134 adults with severe eosinophilic asthma included in the Dutch severe asthma registry (RAPSODI), who initiated reslizumab treatment (4-weekly infusions, 0.3 mg/kg) before April 2020 and had follow-up data for 6 months and greater. Clinical asthma experts completed surveys on their experience with reslizumab treatment. Results: Overall, reslizumab reduced the exacerbation rate (odds ratio [95% CI] = 0.10 [0.05-0.21]; P < .001), oral corticosteroid use (OR [95% CI], 0.2 [0.0-0.5]; P < .001), and maintenance dose (median [CI], 5.0 [0.0-10.0] to 0.0 [0.0-5.0]; P < .001), with comparable results in biologic-naive reslizumab initiators and switchers. The overall response to reslizumab was graded good or excellent in 59.2% of patients. The additive effectiveness of reslizumab after switching from another biologic was reflected in physicians’ surveys. Conclusions: Real-world data show that reslizumab reduces severe asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma, both in biologic-naive reslizumab initiators and in those who switched from another type 2 biologic. This additional value of reslizumab was recognized by clinical asthma experts.
| Original language | English |
|---|---|
| Pages (from-to) | 2099-2108.e6 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 10 |
| Issue number | 8 |
| Early online date | 2022 |
| DOIs | |
| Publication status | Published - Aug 2022 |
Keywords
- Asthma
- Biologic therapy
- Clinical effectiveness
- Exacerbations
- Glucocorticoids
- IL-5
- Observational study
- Registries
- Reslizumab
- Survey
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, No. 8, 08.2022, p. 2099-2108.e6.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma – First Initiators and Switchers
AU - Hashimoto, Simone
AU - Kroes, Johannes A.
AU - Eger, Katrien A.
AU - Mau Asam, Pearl F.
AU - Hofstee, Hendrik B.
AU - Bendien, Sarah A.
AU - Braunstahl, Gert Jan
AU - Broeders, Marielle E. A. C.
AU - Imming, Leonie M.
AU - Langeveld, Bas
AU - Maitland-van der Zee, Anke H.
AU - Oud, Karen T. M.
AU - Patberg, Kornelis Wiebe
AU - Smeenk, Frank W. J. M.
AU - Romme, Elisabeth A. P. M.
AU - van Bezouw, Maarten J.
AU - van de Ven, Marjo J.
AU - van Veen, Anneke
AU - van Velzen, Edwin
AU - van Veen, Ilonka H. P. A. A.
AU - Weersink, Els J. M.
AU - RAPSODI team
AU - ten Brinke, Anneke
AU - Sont, Jacob K.
AU - Bel, Elisabeth H.
N1 - Funding Information: The Registry of Adult Patients with Severe Asthma for Optimal Disease Management (RAPSODI) is financially supported by an unrestricted grant from GSK, Novartis Pharma, AstraZeneca, Teva, and Sanofi-Genzyme Regeneron. An additional unrestricted grant was received from Teva for this study.J.A. Kroes reports a grant from AstraZeneca. S.A. Bendien has received speaker fees from AstraZeneca, GSK, Teva, and Sanofi. G.-J. Braunstahl reports institutional grants from GSK, TEVA, Chiesi, and AstraZeneca outside the submitted work and participated in advisory boards for AstraZeneca, GSK, ALK Abello, and Sanofi Regeneron. B. Langeveld is part of the advisory board from AstraZeneca. A.-H. Maitland-van der Zee has received research grants outside the submitted work from GSK, Boehringer Ingelheim, and Vertex; she is the principal investigator of a P4O2 (Precision Medicine for more Oxygen) public–private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD, and Novartis); and she has served on advisory boards for AstraZeneca, GSK, and Boehringer Ingelheim with money paid to her institution. F.W.J.M. Smeenk reports that his department has received funds for lectures from AstraZeneca, TEVA, and Chiesi. M.J.T. van de Ven participated in the advisory board from GSK, AstraZeneca, and Chiesi (2020/2021). E.J.M. Weersink reports grants from Novartis, GSK, and Sanofi-Genzyme outside the submitted work. A. ten Brinke reports institutional grants from GSK, TEVA, and Astra Zeneca outside the submitted work and participated in advisory boards for AstraZeneca, TEVA, and Sanofi-Genzyme Regeneron. J.K. Sont reports institutional research grant from AstraZeneca NL outside the submitted work. E.H Bel reports institutional grants from GSK and Teva and personal fees from AstraZeneca, GSK, Sanofi-Genzyme Regeneron, Chiesi, Sterna, and Teva outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: J.A. Kroes reports a grant from AstraZeneca. S.A. Bendien has received speaker fees from AstraZeneca, GSK, Teva, and Sanofi. G.-J. Braunstahl reports institutional grants from GSK, TEVA, Chiesi , and AstraZeneca outside the submitted work and participated in advisory boards for AstraZeneca, GSK, ALK Abello, and Sanofi Regeneron. B. Langeveld is part of the advisory board from AstraZeneca. A.-H. Maitland-van der Zee has received research grants outside the submitted work from GSK, Boehringer Ingelheim , and Vertex; she is the principal investigator of a P4O2 (Precision Medicine for more Oxygen) public–private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips , Quantib-U, Smartfish, SODAQ, Thirona, TopMD, and Novartis); and she has served on advisory boards for AstraZeneca, GSK, and Boehringer Ingelheim with money paid to her institution. F.W.J.M. Smeenk reports that his department has received funds for lectures from AstraZeneca, TEVA, and Chiesi. M.J.T. van de Ven participated in the advisory board from GSK, AstraZeneca, and Chiesi (2020/2021). E.J.M. Weersink reports grants from Novartis , GSK, and Sanofi-Genzyme outside the submitted work. A. ten Brinke reports institutional grants from GSK, TEVA, and Astra Zeneca outside the submitted work and participated in advisory boards for AstraZeneca, TEVA, and Sanofi-Genzyme Regeneron. J.K. Sont reports institutional research grant from AstraZeneca NL outside the submitted work. E.H Bel reports institutional grants from GSK and Teva and personal fees from AstraZeneca, GSK, Sanofi-Genzyme Regeneron, Chiesi, Sterna, and Teva outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: The Registry of Adult Patients with Severe Asthma for Optimal Disease Management (RAPSODI) is financially supported by an unrestricted grant from GSK , Novartis Pharma , AstraZeneca , Teva, and Sanofi-Genzyme Regeneron. An additional unrestricted grant was received from Teva for this study. Publisher Copyright: © 2022 The Authors
PY - 2022/8
Y1 - 2022/8
N2 - Background: Reslizumab, a biologic targeting IL-5, has been shown to reduce asthma exacerbations and maintenance oral corticosteroid use in randomized controlled trials and pre-post studies in patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce, and it is unknown whether reslizumab has added value after switching from another type 2 biologic. Objective: To evaluate (1) the real-world effectiveness of reslizumab on severe asthma exacerbations, maintenance oral corticosteroid use, and overall treatment response, both in biologic-naive patients who initiated reslizumab and in those who switched from another type 2 biologic; and (2) physicians’ experience with reslizumab treatment. Methods: This observational real-world study evaluated data from 134 adults with severe eosinophilic asthma included in the Dutch severe asthma registry (RAPSODI), who initiated reslizumab treatment (4-weekly infusions, 0.3 mg/kg) before April 2020 and had follow-up data for 6 months and greater. Clinical asthma experts completed surveys on their experience with reslizumab treatment. Results: Overall, reslizumab reduced the exacerbation rate (odds ratio [95% CI] = 0.10 [0.05-0.21]; P < .001), oral corticosteroid use (OR [95% CI], 0.2 [0.0-0.5]; P < .001), and maintenance dose (median [CI], 5.0 [0.0-10.0] to 0.0 [0.0-5.0]; P < .001), with comparable results in biologic-naive reslizumab initiators and switchers. The overall response to reslizumab was graded good or excellent in 59.2% of patients. The additive effectiveness of reslizumab after switching from another biologic was reflected in physicians’ surveys. Conclusions: Real-world data show that reslizumab reduces severe asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma, both in biologic-naive reslizumab initiators and in those who switched from another type 2 biologic. This additional value of reslizumab was recognized by clinical asthma experts.
AB - Background: Reslizumab, a biologic targeting IL-5, has been shown to reduce asthma exacerbations and maintenance oral corticosteroid use in randomized controlled trials and pre-post studies in patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce, and it is unknown whether reslizumab has added value after switching from another type 2 biologic. Objective: To evaluate (1) the real-world effectiveness of reslizumab on severe asthma exacerbations, maintenance oral corticosteroid use, and overall treatment response, both in biologic-naive patients who initiated reslizumab and in those who switched from another type 2 biologic; and (2) physicians’ experience with reslizumab treatment. Methods: This observational real-world study evaluated data from 134 adults with severe eosinophilic asthma included in the Dutch severe asthma registry (RAPSODI), who initiated reslizumab treatment (4-weekly infusions, 0.3 mg/kg) before April 2020 and had follow-up data for 6 months and greater. Clinical asthma experts completed surveys on their experience with reslizumab treatment. Results: Overall, reslizumab reduced the exacerbation rate (odds ratio [95% CI] = 0.10 [0.05-0.21]; P < .001), oral corticosteroid use (OR [95% CI], 0.2 [0.0-0.5]; P < .001), and maintenance dose (median [CI], 5.0 [0.0-10.0] to 0.0 [0.0-5.0]; P < .001), with comparable results in biologic-naive reslizumab initiators and switchers. The overall response to reslizumab was graded good or excellent in 59.2% of patients. The additive effectiveness of reslizumab after switching from another biologic was reflected in physicians’ surveys. Conclusions: Real-world data show that reslizumab reduces severe asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma, both in biologic-naive reslizumab initiators and in those who switched from another type 2 biologic. This additional value of reslizumab was recognized by clinical asthma experts.
KW - Asthma
KW - Biologic therapy
KW - Clinical effectiveness
KW - Exacerbations
KW - Glucocorticoids
KW - IL-5
KW - Observational study
KW - Registries
KW - Reslizumab
KW - Survey
UR - http://www.scopus.com/inward/record.url?scp=85130484927&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jaip.2022.04.014
DO - https://doi.org/10.1016/j.jaip.2022.04.014
M3 - Article
C2 - 35487369
SN - 2213-2198
VL - 10
SP - 2099-2108.e6
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 8
ER -